Navigation Links
Pandemic Influenza Global Clinical Trials Review, H1, 2016
Date:2/23/2016

NEW YORK, Feb. 23, 2016 /PRNewswire/ -- Pandemic Influenza Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Pandemic Influenza Global Clinical Trials Review, H1, 2016" provides an overview of Pandemic Influenza clinical trials scenario. This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Read the full report: http://www.reportlinker.com/p03638478-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Pandemic Influenza Global Clinical Trials Review, H2, 2015
2. Halyard Health Awarded Federal Contract to Research and Develop High-speed Machine to Produce Respirators for Use During Pandemics
3. Pandemic Influenza Therapeutic Pipeline Review H1 2015 Research Report
4. Prostate Cancer is Pandemic (World Wide) While the Rate of Failure is Epidemic!
5. NanoBio Awarded Up To $10 Million In NIH Funding To Develop A Pandemic Influenza Vaccine
6. Haemophilus influenzae Type B Infections Global Clinical Trials Review, H2, 2015
7. Haemophilus influenzae Infections Global Clinical Trials Review, H2, 2015
8. "The 4th WHO Informal Consultation for Improving Influenza Vaccine Virus Selection" - A Global Meeting Co-organized by WHO and PolyU
9. CSL brands worlds no. 2 influenza vaccine provider as Seqirus
10. HSRx Group Completes Influenza Prevention Phase in Study of Novel Combination Drug for Flu Prevention & Treatment
11. NVS Influenza Vaccines Welcomes North Carolina Congresswoman Renee Ellmers on Tour of Holly Springs Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2019)... ... June 12, 2019 , ... Through their Sidewalk Angels Foundation (SWA), Marisol ... importance of protecting your entire family from Lyme and other tick-borne diseases. We are ... fur we have. , Through this partnership SWA and GLA look to raise ...
(Date:6/11/2019)... ... , ... Today NASH kNOWledge hosted a Liver Disease Information ... Steatohepatitis (NASH) Day, a global effort in the fight against NASH. Community leaders ... what they can do to help. The event also included a pre-screening of ...
(Date:6/11/2019)... China, and SAN DIEGO (PRWEB) , ... June ... ... and fully integrated global Contract Development and Manufacturing Organization (CDMO) serving the global ... announced the appointment of Wei Chen, Ph.D as the company's new Chief Executive ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... Hard money lenders like Monroe ... and the funds can also be provided quickly. If the documentation and collateral are ... are able to avoid the federal oversight involved with a traditional lender, which allows ...
(Date:6/13/2019)... ... 2019 , ... Many people with back pain that radiates down their legs ... widely misunderstood and so are its treatments, according to Kaliq Chang, MD, double board-certified ... , “Sciatica is commonly used to describe nerve-like pain traveling down the legs, often ...
(Date:6/13/2019)... ... June 13, 2019 , ... GlycoMark, Inc. ... at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test ... an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose levels in patients ...
(Date:6/12/2019)... ... June 12, 2019 , ... In September of 2018, NVNA and Hospice ... and remote patient monitoring. Following its full-scale launch in March, NVNA has expanded its ... the beginning of 2019, NVNA has achieved an average all-cause hospital readmissions rate of ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... and developmental disabilities and their families recently received the promise of a two-million-dollar ... grant, gifted by The Tomlinson Foundation, would allow TERI to complete phase two ...
Breaking Medicine News(10 mins):